# A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

> **NCT05848739** · PHASE1 · RECRUITING · sponsor: **Sapience Therapeutics** · enrollment: 130 (estimated)

## Conditions studied

- Colon Cancer
- Metastatic Colon Cancer

## Interventions

- **DRUG:** ST316
- **DRUG:** FOLFIRI regimen & bevacizumab
- **DRUG:** Fruquintinib
- **DRUG:** Lonsurf & bevacizumab

## Key facts

- **NCT ID:** NCT05848739
- **Lead sponsor:** Sapience Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848739, "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05848739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*